or Try an Advanced Search...

    Technical Analysis for ERAS - Erasca, Inc

    Grade Last Price % Change Price Change
    C 2.44 3.39% 0.08
    ERAS closed up 3.39 percent on Monday, July 1, 2024, on 4.59 times normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Up Up
    Historical ERAS trend table...
    Date Alert Name Type % Chg
    MACD Bullish Centerline Cross Bullish 0.00%
    Pocket Pivot Bullish Swing Setup 0.00%
    Volume Surge Other 0.00%
    Stochastic Reached Overbought Strength 0.00%
    Wide Bands Range Expansion 0.00%
    Overbought Stochastic Strength 0.00%
    Up 3 Days in a Row Strength 0.00%
    Up 4 Days in a Row Strength 0.00%
    20 DMA Support Bullish 3.39%
    50 DMA Support Bullish 3.39%
    Older End-of-Day Signals for ERAS ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakout about 5 hours ago
    2x Volume Pace about 6 hours ago
    1.5x Volume Pace about 6 hours ago
    3x Volume Pace about 6 hours ago
    Down 1% about 6 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    ERAS Chart by TradingView
    Basic chart:

    Profile

    Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of NSCLC, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. The company was incorporated in 2018 and is headquartered in San Diego, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Cancer Acute Myeloid Leukemia Colorectal Cancer Enzymes Tyrosine Kinase Receptors Oncogenes NSCLC Non Small Cell Lung Carcinoma Metastatic Solid Tumors Bemcentinib Ras Gtpase Ptpn11

    Is ERAS a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 18 Erasca kicks off Phase III trial for naporafenib combo therapy in melanoma
    Jun 18 Erasca Initiates SEACRAFT-2 Pivotal Phase 3 Trial Evaluating Naporafenib Plus Trametinib in Patients with NRAS-Mutant Melanoma
    Jun 4 Should You Buy Erasca, Inc. (ERAS) After Golden Cross?
    May 29 Erasca to Present at Upcoming Investor Conferences in June
    May 23 Independent Director of Erasca Picks Up 14% More Stock
    May 21 Erasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
    May 17 Erasca stock climbs 10% amid pipeline restructuring, equity offering
    May 17 Erasca restructures; Novartis moves to complete MorphoSys deal
    May 17 DXC Technology Issues Weak Outlook, Joins Take-Two Interactive And Other Big Stocks Moving Lower In Friday's Pre-Market Session
    May 17 Erasca prices $160M equity offering
    See more ERAS news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 2.97
    52 Week Low 1.51
    Average Volume 2,296,157
    200-Day Moving Average 2.10
    50-Day Moving Average 2.18
    20-Day Moving Average 2.27
    10-Day Moving Average 2.17
    Average True Range 0.16
    RSI (14) 60.32
    ADX 13.43
    +DI 26.72
    -DI 20.28
    Chandelier Exit (Long, 3 ATRs) 2.21
    Chandelier Exit (Short, 3 ATRs) 2.45
    Upper Bollinger Bands 2.64
    Lower Bollinger Band 1.90
    Percent B (%b) 0.73
    BandWidth 32.37
    MACD Line 0.01
    MACD Signal Line -0.01
    MACD Histogram 0.019
    Fundamentals Value
    Market Cap 368.65 Million
    Num Shares 151 Million
    EPS -1.73
    Price-to-Earnings (P/E) Ratio -1.41
    Price-to-Sales 0.00
    Price-to-Book 0.78
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.64
    Resistance 3 (R3) 2.63 2.55 2.61
    Resistance 2 (R2) 2.55 2.50 2.56 2.60
    Resistance 1 (R1) 2.50 2.47 2.52 2.51 2.59
    Pivot Point 2.42 2.42 2.43 2.42 2.42
    Support 1 (S1) 2.36 2.36 2.39 2.37 2.29
    Support 2 (S2) 2.28 2.33 2.29 2.28
    Support 3 (S3) 2.23 2.28 2.27
    Support 4 (S4) 2.24